<?xml version="1.0" encoding="UTF-8"?>
<p>Using the CLSI-based assays, several antifungal agents have been assessed for their activity against mycetoma causative agents. These include the polyene amphotericin B; the azoles ketoconazole, itraconazole, posaconazole, fluconazole, voriconazole, isavuconazole and ravuconazole; the allylamine terbinafine; the pyrimidine analogue 5-flucytosine; the echinocandins caspofungin, anidulafunin and micafungin; and the orotomide olorofim (Table 
 <xref rid="tbl3" ref-type="table">3</xref>). Of these, the polyene amphotericin B forms pores in the ergosterol membrane, the azoles and the allylamines inhibit ergosterol synthesis at different stages, the pyrimidine analogue 5-flucytosine competes with pyrimide and the orotomide olorofim inhibits pyrimidine biosynthesis. The echinocandins inhibit 1,3-β-glucan synthesis (Figure 
 <xref ref-type="fig" rid="fig2">2</xref>). As can be seen in Table 
 <xref rid="tbl3" ref-type="table">3</xref>, the most common causative agent, 
 <italic>M. mycetomatis</italic>, has low MICs for the azoles (median MIC50 0.03 µg/ml)
 <xref rid="bib17" ref-type="bibr">
  <sup>17</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib28" ref-type="bibr">
  <sup>28</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib32" ref-type="bibr">
  <sup>32</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib37" ref-type="bibr">
  <sup>37</sup>
 </xref> and olorofim (MIC50 0.016 µg/ml),
 <xref rid="bib35" ref-type="bibr">
  <sup>35</sup>
 </xref> slightly higher MICs for amphotericin B (MIC50 0.5 µg/ml)
 <xref rid="bib17" ref-type="bibr">
  <sup>17</sup>
 </xref> and terbinafine (MIC50 8 µg/ml)
 <xref rid="bib32" ref-type="bibr">
  <sup>32</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib37" ref-type="bibr">
  <sup>37</sup>
 </xref> and is not inhibited by 5-flucytosine
 <xref rid="bib17" ref-type="bibr">
  <sup>17</sup>
 </xref> and the echinocandins.
 <xref rid="bib40" ref-type="bibr">
  <sup>40</sup>
 </xref> The lowest MICs were obtained for ravuconazole,
 <xref rid="bib28" ref-type="bibr">
  <sup>28</sup>
 </xref> the drug currently clinically investigated.
 <xref rid="bib41" ref-type="bibr">
  <sup>41</sup>
 </xref> The sibling species 
 <italic>M. pseudomycetomatis</italic> and 
 <italic>M. tropicana</italic> have a similar susceptibility profile,
 <xref rid="bib36" ref-type="bibr">
  <sup>36</sup>
 </xref> while 
 <italic>M. fahalii</italic> has higher MIC50s for itraconazole (MIC &gt;16 µg/ml) and fluconazole (MIC &gt;256 µg/ml).
 <xref rid="bib36" ref-type="bibr">
  <sup>36</sup>
 </xref>
</p>
